Kura Oncology (KURA) Receivables - Accured (2020 - 2026)

Kura Oncology (KURA) has 7 years of Receivables - Accured data on file, last reported at $4.3 million in Q1 2026.

• On a quarterly basis, Receivables - Accured rose 10.26% year-over-year to $4.3 million in Q1 2026; TTM through Mar 2026 was $4.3 million, a 10.26% increase from a year earlier, with the FY2025 full-year figure at $3.8 million, up 15.15% from the prior year.
• Receivables - Accured for Q1 2026 stood at $4.3 million, up from $3.8 million in the prior quarter.
• Over the last five years, Receivables - Accured for KURA reached as high as $4.3 million in Q1 2026 and fell as low as $900000.0 in Q4 2022.
• Historically, Receivables - Accured has averaged $2.1 million across 5 years, with a median of $1.6 million in 2022.
• Across the five-year window, Receivables - Accured sank 43.75% in 2023 and surged 200.0% in 2024, its largest moves.
• Year by year, Receivables - Accured stood at $900000.0 in 2022, then increased by 22.22% to $1.1 million in 2023, then jumped by 200.0% to $3.3 million in 2024, then climbed by 15.15% to $3.8 million in 2025, then grew by 13.16% to $4.3 million in 2026.
• Per Business Quant data, the three most recent Receivables - Accured figures were $4.3 million in Q1 2026, $3.8 million in Q4 2025, and $3.3 million in Q3 2025.